Preliminary side effect profile, safety, and tolerability of hormonal contraception among women receiving opioid-agonist therapy.

Objective(s): To characterize for the first time the side effect profile, safety, and tolerability of hormonal contraception among women receiving opioid-agonist therapy.

Study Design: We conducted a secondary analysis of data collected from participants in a three-arm randomized controlled trial (N = 138) aimed at increasing effective contraceptive use among women receiving opioid-agonist therapy. Participants in the 2 intervention conditions (n = 90) had free access to hormonal contraception at each of the 14 visits scheduled during the 6-month intervention.

Perceptions of long-acting reversible contraception among women receiving medication for opioid use disorder in Vermont.

Objectives: To evaluate perceptions of long-acting reversible contraceptives (LARC) among women receiving medication for opioid use disorder.

Study Design: Cross-sectional survey of 200 women receiving medication for opioid use disorder in Vermont.

Results: A considerable proportion of women receiving medication for opioid use disorder in Vermont reported previous use of an IUD (40%) and/or a subdermal contraceptive implant (16%); the majority of prior LARC users were satisfied with their IUD (68%) or their implant (74%).

Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes.

Objective: Chromium picolinate (CrPic) supplementation has been suggested to improve glycemia, but there are conflicting reports on efficacy. We sought to determine the effect of CrPic on insulin sensitivity, glycemic control, and body composition in subjects with type 2 diabetes.

Research Design And Methods: Thirty-seven subjects with type 2 diabetes were evaluated.